Canada’s Sernova (TSX: SVA) has entered into a pre-clinical research collaboration with AstraZeneca (LSE: AZN), centered around its Cell Pouch System.
Sernova is focused on developing novel cell therapeutics, with the goal of creating a functional cure for insulin-dependent diabetics.
The Cell Pouch System is a novel implant which naturally vascularize with surrounding tissues, creating an environment for the production and release of absent or under-expressed hormones and proteins.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze